Methods and apparatuses for utilizing an integrated, automated aerating device for echogenicity are described. The aeration device can have a pressurized vessel to provide echogenic air bubbles independently of fluid delivered for sonohsyterosalpingography. The aeration device can selectively supply a gas in liquid during ultrasound and radiographic procedures for enhanced visualization of the uterine cavity and fallopian tubes.

A diffusing applicator is provided and generally includes a head unit, and extension shaft, and a dispensing device. The head unit includes a fluid receiving space and a plurality of dispensing passageways in communication the fluid receiving space. The extension shaft is securely connected to head unit. The dispensing device holds a fluid and is connected to the extension shaft. The dispensing device is in communication with the plurality of dispensing passageways.

A medical elongated body including a shaft portion comprising a linear body and a proximal portion; a distal member disposed in a distal side of the shaft portion and having a distal end and a proximal end, the distal member having a first region having an inner layer and an outer layer which are made of a resin material, and a second region having the inner layer and the outer layer, and a tubular member made of a metallic material and disposed between the inner layer and the outer layer in the second region, the proximal end opening portion comprising an inclined region having a proximally-decreasing dimension; and a reinforcement layer comprising a metallic material arranged between the inner layer and the outer layer from the first region to the second region of the distal member.

Contrast administration data that relates to operation of a contrast media injector system (602) may be converted from at least one format (e.g., a CAN-compliant format) to at least one other format (e.g., an HL-7-compliant format) by an injection data management module (660) for use by a medical system (600). Data on contrast media prescribed for an imaging operation using an imaging system (690), contrast media data for use in this imaging operation, and data on contrast media actually administered/injected by a contrast media injector system (602) for this imaging operation may be stored in a data structure (780) on the injection data management module (660). Patient renal function data may be used to control the dispensing of contrast media from a contrast media/storage/dispensing unit (500), to control the operation of the contrast media injector system (602), or both, and may be stored in the data structure (780) as well.

The inventions provided herein relate to tissue markers and uses thereof, e.g., to mark a target tissue site (e.g., a biopsy site in a breast tissue) or to produce a cell scaffold. The tissue markers described herein are designed to be resistant to fast migration (e.g., immediate migration after implantation through a needle track) and slow migration (e.g., over an extended period of time) upon implantation at a target tissue site (e.g., a biopsy site in a breast tissue), without using an adhesive. Additionally or alternatively, the tissue markers described herein can be readily detectable by at least one imaging modality, e.g., but not limited to magnetic resonance imaging, X-ray imaging, ultrasound imaging, or a combination thereof.

The inventions provided herein relate to injection applicators, tissue markers and uses thereof, e.g., to mark a target tissue site (e.g., a biopsy site in a breast tissue) or to produce a cell scaffold. The tissue markers described herein are designed to be resistant to fast migration (e.g., immediate migration after implantation through a needle track) and slow migration (e.g., over an extended period of time) upon implantation at a target tissue site (e.g., a biopsy site in a breast tissue), without using an adhesive. Additionally or alternatively, the tissue markers described herein can be readily detectable by at least one imaging modality, e.g., but not limited to magnetic resonance imaging, X-ray imaging, ultrasound imaging, or a combination thereof.

A multi-lumen catheter for monitoring uterine contraction pressure having an elongated body configured and dimensioned for insertion into a bladder of a patient, the catheter having a first lumen, a second lumen, and a first balloon at a distal portion, the first lumen communicating with the first balloon. The second lumen communicates with the bladder to remove fluid from the bladder. The first balloon is filled with a gas to form along with the first lumen a gas filled chamber to monitor pressure within the bladder to thereby monitor uterine contraction pressure of the patient.

Provided are a light source unit for an endoscope and an endoscopy system, which clarify the color difference between a first dye and a second dye in an observation image. The light source unit has a white LED light source and a band limiting section. The white LED light source has an excitation light source that emits blue excitation light and a phosphor layer that emits yellow fluorescence upon receipt of the excitation light. As a mixture of the fluorescence and part of the excitation light, the white LED light source outputs light having an intensity spectrum continuous across blue, green and red regions. The band limiting section reduces part of the output light in a wavelength band of not lower than a threshold. The threshold is not less than 650 nm. At the threshold, the first dye (pyoktanin) has an optical reflectance of not less than a constant value, whereas the second dye (indigocarmine) has an optical reflectance of substantially zero.

Apparatuses and methods described herein relate to treating cancerous tumors using radiation therapy and chemotherapy. In some embodiments, a method of treatment includes administering radiation therapy targeting a tumor, isolating a segment of a vessel proximate to the tumor, and administering a dose of a chemotherapeutic agent to the segment of the vessel. The method can further include waiting a period of time after administering the radiation therapy before administering the dose of the chemotherapeutic agent. In some embodiments, a catheter device including first and second occluding elements can be used to isolate the segment of the vessel.

Disclosed is a digestive tract patency capsule, comprising an outer membrane (2) and a supporting material (1) which is soluble in digestive juices. The outer membrane (2) is a sealed soft capsule body made from a sustained-release enteric material, and the dissolution time of the outer membrane (2) is greater than the normal emptying time of the human digestive tract. The cavity of the capsule body of the outer membrane (2) is provided with an indicator (5) which can be absorbed by the body and enables the discharged urine to change color. The supporting material (1) is provided in the cavity of the capsule body of the outer membrane (2) to support the outer membrane (2) in a capsule form. The digestive tract patency capsule can safely and effectively check the feasibility of performing a capsule endoscopic examination on a user. The digestive tract patency capsule can predict the feasibility of a capsule endoscopic examination and is taken before performing a capsule endoscopic examination on a patient, thus safely, simply and effectively providing a good basis for the determination of whether a capsule endoscopic examination should be performed for a clinician.